Skip to content

Role of Injectable Platelet Rich Fibrin in treatment of Oral Lichen Planus

Comparative Efficacy Of Two Dosage Regimens Of Injectable Platelet Rich Fibrin for Management Of Symptomatic Oral Lichen Planus - NIL

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089517
Enrollment
50
Registered
2025-06-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Injectable platelet rich fibrin administered at 14 day interval in patients with Oral lichen planus: The test side will receive PRF injections at 14 day interval as treatment. Liquid

Sponsors

POST GRADUATE INSTITUTE OF DENTAL SCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically symptomatic cases of oral lichen planus (According to Anderson classification Clinical oral lichen planus confirmed through histopathology in accordance with WHO criteria7. Patient who gives written consent to participate in the study.

Exclusion criteria

Exclusion criteria: Patient under the age of 18 years Histopathological signs of moderate to severe dysplasia Genital or cutaneous involvement History of topical or systemic corticosteroid therapy within three months of recruitment. patients with Hemoglobin levels less than 9 gm/dl and platelet count less than 1 lakh/dl. Patients with known haematological disease, chronic liver disease and psychiatric disorders. Smokers or chewable tobacco users. Pregnant or lactating females.

Design outcomes

Primary

MeasureTime frame
1. Changes in size of the lesion. 2. Change in intensity of pain. Timepoint: baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks and 3 months follow up

Secondary

MeasureTime frame
o Patient satisfaction o Number of episodes of new lesions in the follow up period. o Adverse effect of injectable PRF Timepoint: baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks and 3 months follow up

Countries

India

Contacts

Public ContactDR AMBIKA GUPTA

PGIDS, ROHTAK

shahinabeegumsk7@gmail.com09315903300

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026